更新于：2024-11-09
Albenatide
艾本那肽
更新于：2024-11-09
概要
基本信息
原研机构- |
在研机构 |
非在研机构 |
最高研发阶段申请上市 |
首次获批日期- |
最高研发阶段(中国)申请上市 |
特殊审评- |
登录后查看时间轴
序列信息
Sequence Code 3958
来源: *****
Sequence Code 37437
来源: *****
关联
12
项与 艾本那肽 相关的临床试验Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years
评价健康受试者皮下注射CJC-1134-PC注射液分别与二甲双胍、阿托伐他汀、华法林药物-药物相互作用的临床研究
一项多中心、随机、双盲、安慰剂对照III期临床研究以评价在接受二甲双胍单药或二甲双胍联合胰岛素促泌剂治疗后血糖控制不佳的2型糖尿病患者中CJC-1134-PC注射液每周给药1次的有效性和安全性
100 项与 艾本那肽 相关的临床结果
登录后查看更多信息
100 项与 艾本那肽 相关的转化医学
登录后查看更多信息
100 项与 艾本那肽 相关的专利（医药）
登录后查看更多信息
18
项与 艾本那肽 相关的文献（医药）2024-06-01European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
Staging laparoscopy with peritoneal lavage to identify peritoneal metastases and free intraperitoneal cancer cells in the management of locally advanced gastric cancer
Article
作者: Nilsson, M ; Ri, M ; Huang, B ; Rampulla, V ; Rouvelas, I ; Lindblad, M ; Klevebro, F
INTRODUCTION:
Gastric cancer often presents in advanced stage with a significant risk for peritoneal dissemination. Staging laparoscopy can be used to detect peritoneal carcinomatosis (PC+) and free cancer cells in peritoneal lavage cytology (CY+). The current study aimed to present the outcomes of staging laparoscopy and the prognosis of PC+ and CY+ in a Swedish high-volume center.
MATERIALS AND METHODS:
A cohort study including all consecutive patients with locally advanced gastric cancer who underwent staging laparoscopy between February 2008 and October 2022. The laparoscopy findings were categorized as PC+, PC-CY+ (positive cytology without peritoneal carcinomatosis) or negative laparoscopy (PC-CY-). The primary endpoint was overall survival (OS) stratified by laparoscopy findings. The secondary endpoint was OS within each laparoscopy finding group stratified by subsequent treatment.
RESULTS:
Among 168 patients who underwent staging laparoscopy, 78 patients (46%) had PC-CY-, 29 patients (17%) had PC-CY+ and 61 patients (36%) had PC+. Decreased OS was observed for both PC-CY+ patients (aHR 2.14, 95% CI 1.13-4.06) and PC+ patients (aHR 5.36, 95% CI 3.21-8.93), compared to PC-CY-. Patients with PC-CY+ who converted to PC-CY- after chemotherapy and underwent tumor resection seemed to have a better prognosis compared to patients with persisting PC-CY+.
CONCLUSIONS:
Staging laparoscopy is an important tool in the staging of locally advanced gastric cancer. Tumor resection for patients with PC-CY+ who convert to PC-CY- may lead to improved survival for these patients.
2024-01-01Japanese journal of ophthalmology
Corneal refractive error and astigmatism in patients aged 6 to 18 years with a history of retinopathy of prematurity and birth weight of <1500 g
Article
作者: Noda, Toru ; Yuzurihara, Daisuke ; Ueno, Ritsuko ; Mita, Tetsuko ; Tachikawa, Takako
PURPOSE:
To investigate corneal refractive power (CR) and astigmatism (AS) in 6- to 18-year-old children with a history of retinopathy of prematurity (ROP) and birth weight of <1500 g who either did or did not undergo retinal photocoagulation (PC).
STUDY DESIGN:
Retrospective study.
METHODS:
We examined 143 eyes of 77 children in 2021. The children were divided into three groups for evaluation of CR and AS: those with a birth weight of ≥2500 g (normal birth weight [NBW] group, 13 eyes) as controls, those with spontaneously resolved ROP (sr-ROP group, 27 eyes), and those who underwent PC for treatment of ROP (PC-ROP group, 103 eyes). Swept-source anterior segment optical coherence tomography was used to analyze the cornea.
RESULTS:
The median CR in the NBW, sr-ROP, and PC-ROP groups was 42.2 (41.3, 42.8) diopters (D), 44.5 (43.2, 45.5) D, and 45.2 (43.8, 46.6) D, respectively. The median AS in the NBW, sr-ROP, and PC-ROP groups was 1.2 (1.0, 1.5) D, 1.1 (0.8, 1.6) D, and 2.1 (1.4, 2.7) D. In the PC-ROP group, the with-the-rule astigmatic axis was 97%. In all three groups, a strong positive correlation was found between the mean anterior and posterior CR (NBW: r=0.795, sr-ROP: r=0.842, PC-ROP: r=0.890) and AS (NBW: r=0.883, sr-ROP: r=0.841, PC-ROP: r=0.860).
CONCLUSION:
CR was significantly higher in the sr-ROP (p=0.013) and PC-ROP (p<0.001) groups than in the NBW group. The PC-ROP group had significantly more AS than the sr-ROP group. There was a strong correlation between the anterior and posterior CR and AS.
2023-12-01International journal of biological macromolecules
Antimicrobial and anti-SARS-CoV-2 activities of smart daclatasvir-chitosan/gelatin nanoparticles-in-PLLA nanofibrous medical textiles; in vitro, and in vivo study
Article
作者: Elkashlan, Akram M ; Hamdi, Mohamed ; Hammad, Mohamed A ; Ali, Isra H
This study aims at the development of electrospun polylactic acid nanofibers (PLLA NFs) incorporating smart daclatasvir-loaded chitosan gelatin nanoparticles to be used as medical textiles. First, smart nanoparticles were prepared through ionic gelation and optimized using Design Expert® software where daclatasvir (DAC), chitosan (CS), and gelatin (GL) amounts were selected to be the independent variables. DAC was used owing to its reported Anti-SARS-CoV-2 activity, CS was chosen due to its antimicrobial activity and GL was used owing to its sensitivity to be hydrolyzed upon exposure to Papain-like protease enzyme (PLpro). The optimum DAC-CS/TAN NPs possessed 109 nm size and 94.44 % entrapment efficiency in addition to sustained drug release for 14 days. Furthermore, upon exposure to PLpro, smart DAC-CS/GL NPs released the whole DAC amount within 3 h. Then, DAC-CS/GL NPs were incorporated within PLLA NFs through electrospinning. Swellability was found to increase gradually reflecting the controlled release of DAC from nanofibers within 3 weeks. Cell viability assessments using human fibroblasts showed that the developed nanofibers possess high biocompatibility. An in-vivo animal model for skin irritation was carried out for two weeks where visual inspection and histopathological investigations showed that neither edema nor erythema were observed.
100 项与 艾本那肽 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 2型糖尿病 | 申请上市 | 中国 | 2024-04-25 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 73 | (Arm 1 - Weekly CJC-1134-PC) | 憲夢觸願餘膚獵獵積蓋(窪遞餘艱觸艱鑰構夢蓋) = 構窪製製膚鑰餘構鹹夢 窪觸衊願夢夢鑰願蓋壓 (簾鏇淵鏇網築醖網鏇齋, 憲蓋壓壓鹹鏇淵餘鹹憲 ~ 艱壓願鹹艱繭選膚廠鑰) 更多 | - | 2017-07-19 | ||
(Arm 2 - Weekly CJC-1134-PC) | 憲夢觸願餘膚獵獵積蓋(窪遞餘艱觸艱鑰構夢蓋) = 襯糧鏇蓋衊餘衊積積願 窪觸衊願夢夢鑰願蓋壓 (簾鏇淵鏇網築醖網鏇齋, 廠蓋範衊艱蓋願窪願糧 ~ 願壓壓壓製憲壓觸窪鏇) 更多 | ||||||
临床2期 | 90 | (1.5 mg CJC-1134-PC) | 鑰網廠壓齋醖範淵構餘(鏇艱艱觸顧繭醖遞糧積) = 壓艱網糧鹽醖範壓壓觸 蓋齋製範艱壓製蓋鑰鹽 (獵選齋鏇壓觸餘鑰糧積, 鏇憲鹹積淵積遞構觸艱 ~ 鏇積遞艱餘網積醖顧製) 更多 | - | 2017-06-02 | ||
(1.5 mg or 2.0 mg CJC-1134-PC) | 鑰網廠壓齋醖範淵構餘(鏇艱艱觸顧繭醖遞糧積) = 襯醖餘築遞襯衊鏇遞窪 蓋齋製範艱壓製蓋鑰鹽 (獵選齋鏇壓觸餘鑰糧積, 鑰憲簾鏇範築選願積餘 ~ 夢蓋鹽觸艱鑰憲夢鹹繭) 更多 | ||||||
临床2期 | 122 | (1.5 mg CJC-1134-PC) | 遞衊構選齋廠襯鏇觸鹹(鬱選壓醖廠窪簾齋製遞) = 襯構製齋醖築選簾憲鬱 製衊製壓觸憲憲網壓鑰 (窪繭築鏇窪觸齋鏇鑰遞, 遞艱築齋窪顧簾構構衊 ~ 觸築簾夢築顧觸簾齋鏇) 更多 | - | 2017-06-02 | ||
(1.5 or 2.0 mg CJC-1134-PC) | 遞衊構選齋廠襯鏇觸鹹(鬱選壓醖廠窪簾齋製遞) = 築襯壓積壓壓製蓋繭繭 製衊製壓觸憲憲網壓鑰 (窪繭築鏇窪觸齋鏇鑰遞, 顧鑰獵憲憲廠獵鹽壓餘 ~ 膚膚鑰襯糧顧繭鹽鹽選) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用